Chimeric Therapeutics is trading 7.1% down today at A$0.04 as the stock extends its recent slide from A$0.05 amid a lack of fresh catalysts.
- No company-specific announcements or sector-wide news have been released to explain the move.
- The decline appears to reflect ongoing investor caution toward this high-risk micro-cap biotech rather than a new, identifiable event.